Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: Plasma amyloid‐β (Aβ) peptide levels have been examined as a low‐cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community‐based studies to date. Methods: A total of 2189 dementia‐free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ 1‐42 and Aβ 1‐40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results: Increased plasma Aβ 1‐42 levels were associated with lower risk of dementia (Aβ 1‐42: hazard ratio [HR] = 0.80 [0.71‒0.90], P < .001; Aβ 1‐42‐to‐Aβ 1‐40 ratio: HR = 0.86 [0.76‒0.98], P = .027) and AD (Aβ 1‐42: HR = 0.79 [0.69‒0.90], P < .001; Aβ 1‐42‐to‐Aβ 1‐40 ratio: HR = 0.83 [0.72‒0.96], P = .012). Conclusion: Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“CSF levels fall in parallel with increased brain deposition as AD pathology accumulates and, thus, can help refine the differential diagnosis in subjects with clinical dementia [7,8] and identify healthy elderly and individuals with mild cognitive impairment (MCI) who are at high risk of developing AD in the future [9…”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“Thus, following the activity of the amyloid process in asymptomatic subjects could be useful to select those at higher risk of developing AD, for inclusion in clinical trials of putative treatments for AD and, in the future, for preventive interventions [6].”
BackgroundPencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493 · cited 4×
“We then examined whether plasma Ab concentrations improved AD risk prediction when added to models with age, gender, education, and APOE ε4 by computing continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI) [27,28].”
MethodInfluentialJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Epidemiological approaches to heart disease: the Framingham study
Dawber, T. R., Meadors, G. F., & Moore, F. E. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.3.279 · Cited by 2,148 · cited 1×
“It was initiated in 1948 with the enrollment of 5209 women and men aged 28 to 74 years (original cohort) [17].”
BackgroundJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · cited 1×
“Ab42 peptides are suspected to be more prone to aggregate and exert deleterious effects on neurons, than Ab40 peptides [33].”
BackgroundHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“CSF levels fall in parallel with increased brain deposition as AD pathology accumulates and, thus, can help refine the differential diagnosis in subjects with clinical dementia [7,8] and identify healthy elderly and individuals with mild cognitive impairment (MCI) who are at high risk of developing AD in the future [9…”
BackgroundSelf-citationVisser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Cited by
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationAmyloid-β and tau complexity — towards improved biomarkers and targeted therapies
Polanco, J. C., Li, C., Bodea, L.-G., Martinez-Marmol, R., Meunier, F. A., & Götz, J. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 378
70-year legacy of the Framingham Heart Study
Andersson, C., Johnson, A. D., Benjamin, E. J., Levy, D., & Vasan, R. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0202-5 · Cited by 305
O'Bryant, S. E., Mielke, M. M., Rissman, R. A., Lista, S., Vanderstichele, H., Zetterberg, H., Lewczuk, P., Posner, H., Hall, J., Johnson, L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.014 · Cited by 303
Fandos, N., Pérez‐Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., Doecke, J., Fowler, C., Masters, C. L., Sarasa, M., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.07.004 · Cited by 187
Metadata
- Authors
- Chouraki, V., Beiser, A., Younkin, L., Preis, S. R., Weinstein, G., Hansson, O., Skoog, I., Lambert, J., Au, R., Launer, L., Wolf, P. A., Younkin, S., & Seshadri, S.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-09-10
- Volume
- 11
- Issue
- 3
- Pages
- 249
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2099145543
- Cited by
- 120
- References
- 15
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study. https://app.cochat.ai/papers/10.1016/j.jalz.2014.07.001
- The paper
- Chouraki, V., Beiser, A., Younkin, L., Preis, S. R., Weinstein, G., Hansson, O., Skoog, I., Lambert, J., Au, R., Launer, L., Wolf, P. A., Younkin, S., & Seshadri, S. (2015). Plasma amyloid‐β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2014.07.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.